(19)
(11) EP 1 802 641 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.03.2012 Bulletin 2012/10

(45) Mention of the grant of the patent:
10.08.2011 Bulletin 2011/32

(21) Application number: 05824408.8

(22) Date of filing: 07.10.2005
(51) International Patent Classification (IPC): 
C07F 9/38(2006.01)
A61K 31/44(2006.01)
 C07F 9/58(2006.01)
A01N 43/40(2006.01)
(86) International application number:
PCT/US2005/036425
(87) International publication number:
WO 2006/039721 (13.04.2006 Gazette 2006/15)

(54)

BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES

BISPHOSPHONATVERBINDUNGEN UND -VERFAHREN FÜR KNOCHENSCHWUNDKRANKHEITEN, KREBS, KNOCHENSCHMERZEN, IMMUNSTÖRUNGEN UND INFEKTIONSKRANKHEITEN

COMPOSES DE BISPHOSPHONATE ET METHODES DE TRAITEMENT DE MALADIES DE RESORPTION OSSEUSE, DE CANCERS, DE DOULEURS OSSEUSES, DE TROUBLES IMMUNITAIRES ET DE MALADIES INFECTIEUSES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 08.10.2004 US 617108 P
07.10.2005 US 245612

(43) Date of publication of application:
04.07.2007 Bulletin 2007/27

(73) Proprietor: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Urbana, IL 61801 (US)

(72) Inventors:
  • SANDERS, John M.
    Champaign, Illinois 61820 (US)
  • SONG, Yongcheng
    Urbana, Illinois 61801 (US)
  • CHAN, Julian M. W.
    Boston, Massachussetts, 02215 (US)
  • OLDFIELD, Eric
    Champaign, Illinois 61821 (US)
  • ZHANG, Yonghui
    Urbana, IL 61801 (US)

(74) Representative: Lord, Hilton David 
Marks & Clerk LLP 90 Long Acre
London WC2E 9RA
London WC2E 9RA (GB)


(56) References cited: : 
WO-A1-95/34207
 US-A- 4 871 720
   
  • DATABASE CAPLUS [Online] AFER'EV I.S.: 'The reference discloses the compounds of the invention when X is an H, n is 1 and R1-R7 are Hydrogens', XP002998564 Database accession no. 1995:908303
  • AMIN DILIP: 'Bisphosphonates used for the treatment of bobe disorders inhibit squalene synthase and cholesterol biosynthesis' vol. 33, 1992, pages 1657 - 1633, XP008119254
  • DATABASE CAPLUS [Online] 25 July 1980 SUZUKI FUMIO: 'Similar compounds with the pyridyl are disclosed', XP002998565
  • KOTSIKOROU E. ET AL: 'Bisphosponate Inhibition of the Exopolyphosphatase Activity of the Trypanosoma brucei Solube Vacuolar Pyrophoshatase' J. MED. CHEM. vol. 48, no. 19, 11 April 2005, pages 6128 - 6139, XP008119224
  • SANDERS J. ET AL: 'Pyridinium-1-yl Bisphosphonates are Potent Inhibitors of Farnesyl Diphosphate Synthase and Bone Resorption' J.MED.CHEM. vol. 48, no. 8, 2005, pages 2957 - 2963, XP008119225
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).